• ZEO Scientifix agreed on October 26, 2026, to issue Pluri common shares representing a 41% post-issuance stake under a license-for-equity deal.
• At closing, Pluri will also receive 50 shares of newly designated Series D Non-Convertible Preferred Stock.
• In exchange, Pluri will grant exclusive U.S. rights to manufacture and commercialize its present and future regenerative medicine products using its technology.
• Royalties based on net sales will rise in stages as Pluri's equity ownership declines.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ZEO Scientifix Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001829126-26-011800), on October 30, 2026, and is solely responsible for the information contained therein.